Hepatitis is an inflammation of the liver mainly induced by autoimmunity, chemical, or infectious agents. In the United States, the third most prevalent form of chronic infectious hepatitis is caused by hepatitis C virus (HCV). Worldwide there are an estimated 170 million people infected with HCV with nearly 4 million infected individuals in the United States.
>> Learn more
Virobay is developing VBY-376 as a therapeutic agent for HCV infection. VBY-376 blocks viral replication through the specific inhibition of the HCV NS3/4A protease, a target that has been proven through genetic validation and clinical trials to be essential for HCV replication.
VBY‑376 is highly selective protease inhibitor and exhibits potent antiviral activity in cellular models. VBY-376, an investigational compound, represents a potential therapeutic agent with a different mechanism of action than the current standard of care of pegylated interferon and ribavirin.
Based on preclinical pharmacokinetic modelling, once-daily and twice-daily dosing frequencies will be evaluated in upcoming clinical trials.
